Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial

Clinical Immunology

Volumn 127, Issue 2, 2008, Pages 188-197

  Peduzzi, Elisabetta ^a   Westerfeld, Nicole ^b   Zurbriggen, Rinaldo ^b   Pluschke, Gerd ^a   Daubenberger, Claudia A ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b Pevion Biotech Ltd   (Switzerland)

Author keywords

Antigen delivery platform; Apical membrane antigen 1; Circumsporozoite protein 1; Clinical trial; ELISpot analysis; Immuno potentiating reconstituted influenza virosome; Plasmodium falciparum; T cell help

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; GAMMA INTERFERON; IMMUNO POTENTIATING RECONSTITUTED INFLUENZA VIROSOME; INFLUENZA VACCINE; MALARIA VACCINE; PLACEBO; UNCLASSIFIED DRUG; VIROSOME;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE ESCALATION; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FEMALE; HUMAN; INFLUENZA; INFLUENZA VACCINATION; LYMPHOCYTE PROLIFERATION; MALE; PHASE 1 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, PROTOZOAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNITY, CELLULAR; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; MOLECULAR SEQUENCE DATA; ORTHOMYXOVIRIDAE; PLASMODIUM FALCIPARUM; VACCINES, SUBUNIT; VACCINES, VIROSOME;

EID: 41549117443     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.01.012     Document Type: Article

References (31)

1. Westerfeld N., and Zurbriggen R. Peptides delivered by immunostimulating reconstituted influenza virosomes. J. Pept. Sci. 11 (2005) 707-712
2. Moreno R., Jiang L., Moehle K., Zurbriggen R., Gluck R., Robinson J.A., and Pluschke G. Exploiting conformationally constrained peptidomimetics and an efficient human-compatible delivery system in synthetic vaccine design. Chembiochem. 2 (2001) 838-843
3. Poltl-Frank F., Zurbriggen R., Helg A., Stuart F., Robinson J., Gluck R., and Pluschke G. Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine. Clin. Exp. Immunol. 117 (1999) 496-503
4. Pfeiffer B., Peduzzi E., Moehle K., Zurbriggen R., Gluck R., Pluschke G., and Robinson J.A. A virosome-mimotope approach to synthetic vaccine design and optimization: synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate. Angew. Chem., Int. Ed. Engl. 42 (2003) 2368-2371
5. James S., Moehle K., Renard A., Mueller M.S., Vogel D., Zurbriggen R., Pluschke G., and Robinson J.A. Synthesis, solution structure and immune recognition of an epidermal growth factor-like domain from Plasmodium falciparum merozoite surface protein-1. Chembiochem. 7 (2006) 1943-1950
6. Okitsu S.L., Kienzl U., Moehle K., Silvie O., Peduzzi E., Mueller M.S., Sauerwein R.W., Matile H., Zurbriggen R., Mazier D., Robinson J.A., and Pluschke G. Structure-activity-based design of a synthetic malaria peptide eliciting sporozoite inhibitory antibodies in a virosomal formulation. Chem. Biol. 14 (2007) 577-587
7. Zurbriggen R., and Gluck R. Immunogenicity of IRIV versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice. Vaccine 17 (1999) 1301-1305
8. Collins W.E., Pye D., Crewther P.E., Vandenberg K.L., Galland G.G., Sulzer A.J., Kemp D.J., Edwards S.J., Coppel R.L., and Sullivan J.S. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am. J. Trop. Med. Hyg. 51 (1994) 711-719
9. Amante F.H., Crewther P.E., Anders R.F., and Good M.F. A cryptic T cell epitope on the apical membrane antigen 1 of Plasmodium chabaudi adami can prime for an anamnestic antibody response: implications for malaria vaccine design. J. Immunol. 159 (1997) 5535-5544
10. Malkin E.M., Diemert D.J., McArthur J.H., Perreault J.R., Miles A.P., Giersing B.K., Mullen G.E., Orcutt A., Muratova O., Awkal M., Zhou H., Wang J., Stowers A., Long C.A., Mahanty S., Miller L.H., Saul A., and Durbin A.P. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect. Immun. 73 (2005) 3677-3685
11. Saul A., Lawrence G., Allworth A., Elliott S., Anderson K., Rzepczyk C., Martin L.B., Taylor D., Eisen D.P., Irving D.O., Pye D., Crewther P.E., Hodder A.N., Murphy V.J., and Anders R.F. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant. Vaccine 23 (2005) 3076-3083
12. Polhemus M.E., Magill A.J., Cummings J.F., Kester K.E., Ockenhouse C.F., Lanar D.E., Dutta S., Barbosa A., Soisson L., Diggs C.L., Robinson S.A., Haynes J.D., Stewart V.A., Ware L.A., Brando C., Krzych U., Bowden R.A., Cohen J.D., Dubois M.C., Ofori-Anyinam O., De Kock E., Ballou W.R., and Heppner J. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 25 (2007) 4203-4212
13. Dame J.B., Williams J.L., McCutchan T.F., Weber J.L., Wirtz R.A., Hockmeyer W.T., Maloy W.L., Haynes J.D., Schneider I., and Roberts D. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 225 (1984) 593-599
14. Epstein J.E., Giersing B., Mullen G., Moorthy V., and Richie T.L. Malaria vaccines: are we getting closer?. Curr. Opin. Mol. Ther. 9 (2007) 12-24
15. Mueller M.S., Renard A., Boato F., Vogel D., Naegeli M., Zurbriggen R., Robinson J.A., and Pluschke G. Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1. Infect. Immun. 71 (2003) 4749-4758
16. Okitsu S.L., Silvie O., Westerfeld N., Curcic M., Kammer A.R., Mueller M.S., Sauerwein R.W., Robinson J.A., Genton B., Mazier D., Zurbriggen R., and Pluschke G. A virosomal malaria Peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial. PLoS ONE 2 (2007) e1278
17. Genton B., Pluschke G., Degen L., Kammer A.R., Westerfeld N., Okitsu S.L., Schroller S., Vounatsou P., Mueller M.S., Tanner M., and Zurbriggen R. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. PLOS Clin. Trials e1018 (2007) 1-9
18. Singh H., and Raghava GP. ProPred: prediction of HLA-DR binding sites. Bioinformatics 17 (2001) 1236-1237
19. Keilholz U., Martus P., and Scheibenbogen C. Immune monitoring of T-cell responses in cancer vaccine development. Clin. Cancer Res. 12 (2006) 2346s-2352s
20. Knutson K.L., dela R.C., and Disis M.L. Laboratory analysis of T-cell immunity. Front. Biosci. 11 (2006) 1932-1944
21. Schumacher R., Adamina M., Zurbriggen R., Bolli M., Padovan E., Zajac P., Heberer M., and Spagnoli G.C. Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation. Vaccine 22 (2004) 714-723
22. Flanagan K.L., Lee E.A., Gravenor M.B., Reece W.H., Urban B.C., Doherty T., Bojang K.A., Pinder M., Hill A.V., and Plebanski M. Unique T cell effector functions elicited by Plasmodium falciparum epitopes in malaria-exposed Africans tested by three T cell assays. J. Immunol. 167 (2001) 4729-4737
23. Ockenhouse C.F., Angov E., Kester K.E., Diggs C., Soisson L., Cummings J.F., Stewart A.V., Palmer D.R., Mahajan B., Krzych U., Tornieporth N., Delchambre M., Vanhandenhove M., Ofori-Anyinam O., Cohen J., Lyon J.A., and Heppner D.G. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine 24 (2006) 3009-3017
24. Lal A.A., Hughes M.A., Oliveira D.A., Nelson C., Bloland P.B., Oloo A.J., Hawley W.E., Hightower A.W., Nahlen B.L., and Udhayakumar V. Identification of T-cell determinants in natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in an adult population exposed to malaria. Infect. Immun. 64 (1996) 1054-1059
25. Udhayakumar V., Kariuki S., Kolczack M., Girma M., Roberts J.M., Oloo A.J., Nahlen B.L., and Lal A.A. Longitudinal study of natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in a holoendemic region of malaria in Western Kenya: Asembo Bay Cohort Project VIII. Am. J. Trop. Med. Hyg. 65 (2001) 100-107
26. Zhang G.L., Srinivasan K.N., Veeramani A., August J.T., and Brusic V. PREDBALB/c: a system for the prediction of peptide binding to H2d molecules, a haplotype of the BALB/c mouse. Nucleic Acids Res. 33 (2005) W180-W183
27. Bangari D.S., and Mittal S.K. Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24 (2006) 849-862
28. McCoy K., Tatsis N., Korioth-Schmitz B., Lasaro M.O., Hensley S.E., Shih-Wen L., Li Y., Giles-Davis W., Cun A., Zhou D., Xiang Z., Letvin N.L., and Ertl H.C. The effect of pre-existing immunity to antigens of adenovirus of the human serotype 5 on immune responses of nonhuman primates to vaccine regimens based on human or chimpanzee-derived adenovirus vectors. J. Virol. 81 (2007) 6594-6604
29. Brave A., Ljungberg K., Wahren B., and Liu M.A. Vaccine delivery methods using viral vectors. Mol. Pharmacol. 4 (2007) 18-32
30. He X.S., Holmes T.H., Zhang C., Mahmood K., Kemble G.W., Lewis D.B., Dekker C.L., Greenberg H.B., and Arvin A.M. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J. Virol. 80 (2006) 11756-11766
31. Danke N.A., and Kwok W.W. HLA class II-restricted CD4+ T cell responses directed against influenza viral antigens postinfluenza vaccination. J. Immunol. 171 (2003) 3163-3169